Featured Articles

1. LNP-Mediated Cell Transfection In Bioreactors Across Workflows 6/24/2026

   Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.

2. Towards A Universal LNP Platform For Multiplex Engineering 6/19/2026

   Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.

3. Extrahepatic Delivery Of mRNA-LNP To Spleen 6/19/2026

   In vivo CAR-T approaches aim to reprogram T cells directly in the body using targeted lipid nanoparticles. Improved delivery to immune organs highlights new potential for scalable cell therapies.

4. mRNA LNPs Drive Safe, Effective Repeat Dosing In Disease Models 6/19/2026

   Well-designed lipid nanoparticles enable safe, efficient delivery. OVA-based models show how formulation choices shape efficacy, safety, and anti-tumor outcomes in melanoma research.

5. A Practical Guide To Autologous CAR T Manufacturing 6/19/2026

   Early process decisions shape scalability, consistency, and compliance in autologous CAR T manufacturing. Learn where variability emerges across the workflow and how to plan ahead.

6. The Invaluable Asset Driving Advanced Therapies Forward 6/19/2026

   Cell therapies are advancing rapidly, but manufacturing delays still limit patient access. Improving operational understanding, reducing risk, and strengthening collaboration may be just as critical.

7. Achieving High CAR T Cell Transduction Using An Automated Platform 6/19/2026

   Automation is reshaping CAR T manufacturing. A modular, closed approach with digital integration supports efficient workflows while maintaining critical functional performance under GMP conditions.

8. Accelerating Autologous CAR T Cell Expansion With Automation 6/19/2026

   Scaling CAR T manufacturing demands high expansion without exhaustion. Examine integrated, semi-automated approaches with digital traceability that can improve consistency and preserve cell function.

9. A Custom Path To The Clinic: Inside A Collaborative Model 6/19/2026

   Balancing speed, compliance, and control is no small task. A different approach to external support is emerging—one that prioritizes knowledge transfer, collaboration, and long-term confidence.

10. Evaluating CAR T Cell Therapy Processing 6/19/2026

    Serum-free media is reshaping CAR T manufacturing. Gain insight into how media-agnostic platforms offer the flexibility to adapt workflows without re-optimization, helping teams streamline processes.